SCHEMBL10233485

SCHEMBL10233485

CC(C)(C)OC(=O)Nc1ncc(CCC(=O)O)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
CCNE1 P24864 5/20 0.43
CDK2 P24941 5/20 0.43
CCNE2 O96020 3/20 0.43
CCNB2 O95067 2/20 0.43
CDK1 P06493 2/20 0.43
CDK4 P11802 2/20 0.43
CCNB1 P14635 2/20 0.43
CCND1 P24385 2/20 0.43
CCNB3 Q8WWL7 2/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CDK5 Q00535 2/20 0.41
MAPK1 P28482 1/20 0.41
GCK P35557 1/20 0.40
PARG Q86W56 1/20 0.40
OGA O60502 2/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5045601 0.86 ALDH1A1 (0.45) SCDSMN1; SMN2CCNE1CDK2CCNE2
SCHEMBL12725091 0.86 FDPS (0.49) SMN1; SMN2CCNE1CDK2CCNE2CCNB2
SCHEMBL31240467 0.86 MAPK1 (0.45) SCDSMN1; SMN2CCNE1CDK2CCNE2
SCHEMBL10233501 0.86 SMN1; SMN2 (0.41) SMN1; SMN2CCNE1CDK2CCNE2CCNB2
SCHEMBL1939044 0.85 CA1 (0.45) SMN1; SMN2CCNE1CDK2CCNE2CCNB2
SCHEMBL2666855 0.85 ALDH1A1 (0.48) SMN1; SMN2CCNE1CDK2CCNE2CCNB2
SCHEMBL8834765 0.83 CCNE1 (0.52) SMN1; SMN2CCNE1CDK2CCNE2CCNB2
SCHEMBL1031633 0.83 SMN1; SMN2 (0.47) SCDSMN1; SMN2CCNE1CDK2CCNE2
SCHEMBL29170444 0.82 CA1 (0.47) SMN1; SMN2CCNE1CDK2CCNE2CCNB2
SCHEMBL15839429 0.82 SMN1; SMN2 (0.46) SMN1; SMN2CCNE1CDK2CCNE2CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119626-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-02-21 US disclosed
US-8119626-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-02-21 US disclosed
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF SUGAWARA KAZUTOSHI 2009-11-26 US disclosed
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF SUGAWARA KAZUTOSHI 2009-11-26 US disclosed
US-7514439-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
US-7514439-B2 Oxime derivative and preparations thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
US-20080132479-A1 Oxime Derivative and Preparations Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-05 US disclosed
US-20080132479-A1 Oxime Derivative and Preparations Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132479-A1 Oxime Derivative and Preparations Thereof GCK, KHK, GCKR SCD 2097/4885SMN1; SMN2 4216/4885CCNE1 527/4885
US-20090291936-A1 OXIME DERIVATIVE AND PREPARATIONS THEREOF GCK, KHK, GCKR SCD 2097/4885SMN1; SMN2 4216/4885CCNE1 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.